[{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"HUYA Bioscience International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HUYA Bioscience International Appoints Meiji Seika Pharma as Exclusive Distributor For HBI-8000 in Japan and Other Asian Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai to Take Over Manufacturing and Marketing Approval for Equfina\u00ae 50 Mg Tablets (safinamide Mesilate)INn Japan from Meiji Seika Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Dong-A Socio Holdings","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intas Enters License Agreement with Meiji and Dong Commercialize DMB-3115","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meiji Completed Phase I Studies and Moves Onto Phase II Study of ME3183, a Selective PDE4 Inhibitor for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with Plaque Psoriasis in the United States and Canada","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Foundation for Biomedical Research and Innovation at Kobe","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Novel Anti-PD-1 Agonist Antibody with Immunosuppressive Effect Discovered Through Joint Research Between Meiji Seika Pharma and The Foundation for Biomedical Research and Innovation at Kobe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Meiji Seika Pharma
A novel anti-PD-1 agonist monoclonal antibody, which inhibits the function of PD-1 (anti-PD-1 blocking antibodies) leading in enhanced anti-tumor immunity.
In non-clinical studies, ME3183, a selective phosphodiesterase-4 (PDE4) inhibitor, showed greater anti-inflammatory effect and its inhibitory effect on TNF-α production was approximately 30-fold greater than the existing orally-available PDE4 inhibitor for psoriasis.
ME3183 is an orally-available and selective inhibitor for phosphodiesterase 4 (PDE4) discovered by Meiji. In the study, ME3183 has been shown to be safe and well-tolerated across the doses tested.
Under the terms of the agreement, Intas was granted the exclusive license rights to market DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia.
A single subcutaneous injection of DMB3115 in healthy volunteers was well tolerated. The reported adverse events corresponded with the known safety profile of ustekinumab.
Eisai will take over by transfer the manufacturing and marketing approval of Equfina from Meiji. Eisai, as the manufacturer and distributor of Equfina in Japan, will continue to provide information on the proper usage of Equfina.
HUYABIO will complete the development of HBI-8000 for PTCL and ATL in Japan for commercialization by Meiji who will hold exclusive sales and marketing rights.